Navigation Links
BioMarin to Present at the UBS Global Life Sciences Conference
Date:9/14/2010

NOVATO, Calif., Sept. 14 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President, Corporate and Business Development of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New York City on Tuesday, September 21, 2010 at 3:30 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Eugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
2. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
3. BioMarin Acquires ZyStor Therapeutics, Inc.
4. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
5. BioMarin to Acquire LEAD Therapeutics
6. BioMarin to Present at the Credit Suisse Healthcare Conference
7. BioMarin Announces Third Quarter 2009 Financial Results
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Acquires Huxley Pharmaceuticals, Inc.
10. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
11. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Transparency Market Research has ... Insufficiency Market - Global Industry Analysis, Size, Share, Growth, ... the report, the exocrine pancreatic insufficiency market is anticipated ... to 2023 to reach US$2.85 Bn by 2023. ... by the deficiency of the exocrine pancreatic enzymes, causing ...
(Date:5/23/2016)... , May 23, 2016 ... Devices, Diagnostics and Monitoring, and Vision Care ... Which areas are going to grow at the fastest ... revenues to 2026, assessing data, trends, opportunities and prospects. ... charts, and graphs. Discover the most lucrative areas in ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging Society ... Imaging.” The focus of ADDMI-IG will be geared towards how using molecular imaging ... Through ADDMI-IG WMIS will provide a platform for productive discussions about the implementation ...
(Date:5/25/2016)... ... May 25, 2016 , ... TransactRx announces the ... adjudication of medical service claims by Pharmacy Benefit Managers that were submitted by ... software. The TransactRx Cross Benefit Clearinghouse receives standard professional medical claims submitted from ...
(Date:5/25/2016)... ... 2016 , ... For more than fifty years, we've suffered whiplash as each new scientific study ... to the latest nutritional advice – advice that was supposed to keep us healthy and ... 3 American adults are considered to be overweight and more than 1 in 3 adults ...
(Date:5/25/2016)... ... , ... Consumer access to organic foods and grower access to food processers ... grain cereals and other plant-based foods, will introduce the first consumer product (a new ... by Hesco/Dakota Organic Products. , The transitional designation means the cereal was made using ...
(Date:5/24/2016)... ... , ... According to an article published May 11th on Fox ... the amount of calories they consumed by 25% experienced some interesting health benefits. This ... improved quality of life, and enhanced sexual function compared to the other group, which ...
Breaking Medicine News(10 mins):